Wall Street analyst estimates for Silence Therapeutics plc (SLN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.12 | ||
| 2026-08-10 | $-0.26 | $-0.13 | -104.4% |
| 2026-05-07 | $-0.32 | $-0.33 | +3.0% |
| 2026-03-05 | $-0.25 | $-0.32 | +21.9% |
| 2025-11-06 | $-0.45 | $-0.40 | -12.5% |
| 2025-08-07 | $-0.54 | $-0.27 | -100.0% |
| 2025-05-08 | $-0.60 | $-0.18 | -233.3% |
| 2025-02-27 | $0.27 | $-0.45 | +160.0% |
Valuation Ratios
| Price / Book | 5.00 |
| EV / EBITDA | -9.01 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $770000 | $16000 | 0 | $244000 | $5.5M | $12.4M | $17.7M | $25.4M | $43.3M | $559000 |
| Cost of Revenue | $8.7M | $7.9M | $9.7M | 0 | $3.8M | $7.5M | $11.0M | $10.3M | $11.8M | $215000 |
| Gross Profit | -$7.9M | -$7.9M | -$9.7M | $244000 | $1.7M | $5.0M | $6.7M | $15.1M | $31.4M | $344000 |
| Research & Development | $8.7M | $7.9M | $9.7M | $13.3M | $20.2M | $30.8M | $35.5M | $44.0M | $67.9M | $67.8M |
| Selling, General & Admin | $4.0M | $6.5M | $10.8M | $9.6M | $14.0M | $20.0M | $20.9M | $20.6M | $26.9M | $22.3M |
| Operating Expenses | $4.0M | $6.5M | $10.8M | $23.0M | $37.6M | $50.8M | $56.4M | $64.7M | $94.8M | $90.1M |
| Operating Income | -$11.9M | -$14.4M | -$20.6M | -$22.7M | -$35.8M | -$45.8M | -$49.8M | -$49.6M | -$63.3M | -$89.8M |
| EBITDA | -$11.6M | -$3.3M | -$20.2M | -$22.4M | -$35.5M | -$45.4M | -$39.9M | -$49.8M | -$49.0M | -$88.0M |
| Interest Expense | 0 | $15000 | 0 | $33000 | $16000 | $8000 | $47000 | $34000 | 0 | 0 |
| Pre-tax Income | -$10.4M | -$3.8M | -$20.5M | -$22.9M | -$36.0M | -$45.9M | -$40.5M | -$50.3M | -$44.5M | -$88.6M |
| Income Tax | -$1.9M | -$2.2M | -$2.1M | -$3.3M | -$3.5M | -$6.4M | $560854 | -$7.0M | $845000 | $11000 |
| Net Income | -$8.4M | -$1.6M | -$18.4M | -$19.6M | -$32.5M | -$39.4M | -$41.0M | -$43.3M | -$45.3M | -$88.6M |
| EPS | $-0.36 | $-0.07 | $-0.78 | $-0.78 | $-1.11 | $-1.35 | $-3.78 | $-3.48 | $-2.37 | $-5.67 |
| EPS (Diluted) | $-0.36 | $-0.07 | $-0.78 | $-0.78 | $-1.11 | $-1.35 | $-3.78 | $-3.48 | $-2.37 | $-5.67 |
| Shares Outstanding (Diluted) | $23.3M | $23.3M | $23.4M | $25.0M | $27.3M | $29.7M | $10.7M | $12.4M | $15.4M | $15.7M |
Price
| Price | $12.50 |
| Market Cap | $590M |
| Exchange | NASDAQ |
| Country | GB |
Related companies: ACIU · ALDX · AMRN · ANRO · CAPR · CTNM · KYTX
Explore sector: Healthcare · Biotechnology
More sections of SLN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks